Date: 2011-09-19
Type of information:
phase: 1
Announcement: recruitment of the first patients
Company: Glycotope (Germany)
Product: TrasGEX™
Action mechanism: TrasGEX® is a biobetter of the marketed trastuzumab / Herceptin® targeting the HER2-receptor, commonly overexpressed in a variety of cancers. TrasGEX® has been glycooptimized to yield a manifold higher anti-tumor activity and is supposed to be suitable for the treatment of an enlarged patient spectrum. It was developed using GlycoExpress™, the company\'s development and production platform based on glycoengineered human cell lines for biopharmaceuticals with fully human and optimized glycosylation.
Disease: breast cancer
Therapeutic area: Cancer Oncology
Country:
Trial details:
Latest news: Glycotope has announced the enrollment of the first patients in a phase I dose finding trial to evaluate safety and tolerability of TrasGEX®. TrasGEX® is Glycotope’s 4th glycooptimized biopharmaceutical product in clinical trials and their 3rd anti-cancer antibody which entered clinical trials in time.
